Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CRL · Entity 3398 | Director | August 25, 2026 | August 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Report date August 25, 2026 · Filed August 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,596 |
Ending reported balance
After 2026-08-25 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-08-25 · Exercise / conversion · Acquired 21,132 · Balance 52,728 Row 2 · 2026-08-25 · Exercise / conversion · Acquired 12,429 · Balance 65,157 Row 3 · 2026-08-25 · Sale · Disposed 33,561 · Balance 31,596 F1: This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 6, 2026. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $194.12 · Expires 2033-05-26 | Direct | 7,044 |
Reported balance
After 2026-08-25 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-08-25 · Exercise / conversion · Disposed 21,132 · Balance 7,044 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $208.44 · Expires 2034-05-31 | Direct | 12,429 |
Reported balance
After 2026-08-25 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-08-25 · Exercise / conversion · Disposed 12,429 · Balance 12,429 |
| Common StockSEC Table I · non-derivative | Indirect2024 GRAT | 5,423 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 5,423 |
| Common StockSEC Table I · non-derivative | Indirect2025 GRAT | 10,780 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 10,780 |
| Common StockSEC Table I · non-derivative | Indirect2026 GRAT | 20,000 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 20,000 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 155,611 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 155,611 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust Held By Spouse | 10,000 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 10,000 |
Filing footnotes · ownership attribution and instrument terms
F1: This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 6, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2017 Filed Mar 1, 2017 20:34 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $87.15 | $8,714.50 |
DisclosureSEC source: 0001127602-17-009203 · form4.xml · nonDerivative · entry 23 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 397,491 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 20:34 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 300 | $87.14 | $26,142.00 |
DisclosureSEC source: 0001127602-17-009203 · form4.xml · nonDerivative · entry 22 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 397,591 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 20:34 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $87.13 | $8,713.00 |
DisclosureSEC source: 0001127602-17-009203 · form4.xml · nonDerivative · entry 21 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 397,891 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 20:34 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 300 | $87.12 | $26,136.00 |
DisclosureSEC source: 0001127602-17-009203 · form4.xml · nonDerivative · entry 20 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 397,991 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 20:34 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $87.12 | $17,423.00 |
DisclosureSEC source: 0001127602-17-009203 · form4.xml · nonDerivative · entry 19 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,291 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 20:34 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 400 | $87.11 | $34,844.00 |
DisclosureSEC source: 0001127602-17-009203 · form4.xml · nonDerivative · entry 18 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,491 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 20:34 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $87.11 | $8,710.50 |
DisclosureSEC source: 0001127602-17-009203 · form4.xml · nonDerivative · entry 17 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,891 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 20:34 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 500 | $87.10 | $43,550.00 |
DisclosureSEC source: 0001127602-17-009203 · form4.xml · nonDerivative · entry 16 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,991 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 20:34 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $87.10 | $8,709.50 |
DisclosureSEC source: 0001127602-17-009203 · form4.xml · nonDerivative · entry 15 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 399,491 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 20:34 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 500 | $87.09 | $43,545.00 |
DisclosureSEC source: 0001127602-17-009203 · form4.xml · nonDerivative · entry 14 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 399,591 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 20:34 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 392 | $87.08 | $34,135.36 |
DisclosureSEC source: 0001127602-17-009203 · form4.xml · nonDerivative · entry 13 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,091 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 20:34 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $87.07 | $17,414.00 |
DisclosureSEC source: 0001127602-17-009203 · form4.xml · nonDerivative · entry 12 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,483 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 20:34 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 80 | $87.06 | $6,964.40 |
DisclosureSEC source: 0001127602-17-009203 · form4.xml · nonDerivative · entry 11 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,683 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 20:34 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 220 | $87.05 | $19,151.00 |
DisclosureSEC source: 0001127602-17-009203 · form4.xml · nonDerivative · entry 10 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,763 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 20:34 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $87.05 | $8,704.50 |
DisclosureSEC source: 0001127602-17-009203 · form4.xml · nonDerivative · entry 9 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,983 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 20:34 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 216 | $87.03 | $18,798.48 |
DisclosureSEC source: 0001127602-17-009203 · form4.xml · nonDerivative · entry 8 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 401,083 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 20:34 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 102 | $87.02 | $8,876.04 |
DisclosureSEC source: 0001127602-17-009203 · form4.xml · nonDerivative · entry 7 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 401,299 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 20:34 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $87.00 | $8,700.00 |
DisclosureSEC source: 0001127602-17-009203 · form4.xml · nonDerivative · entry 6 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 401,401 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 20:34 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $86.99 | $8,699.00 |
DisclosureSEC source: 0001127602-17-009203 · form4.xml · nonDerivative · entry 5 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 401,501 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 20:34 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $86.98 | $8,698.00 |
DisclosureSEC source: 0001127602-17-009203 · form4.xml · nonDerivative · entry 4 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 401,601 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 20:34 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $86.95 | $8,695.00 |
DisclosureSEC source: 0001127602-17-009203 · form4.xml · nonDerivative · entry 3 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 401,701 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 20:34 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 20,071 | $59.41 | $1,192,418.11 |
DisclosureSEC source: 0001127602-17-009203 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 401,801 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 20:34 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 2,301 | $88.05 | $202,603.05 |
DisclosureSEC source: 0001127602-17-009203 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 381,730 Read SEC document |
| February 26, 2017 Filed Feb 28, 2017 19:31 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 2,409 | $88.05 | $212,112.45 |
DisclosureSEC source: 0001127602-17-008875 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 384,031 Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 19:31 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 96,033 | $0.00 Strike: $88.05 | $0.00 |
DisclosureSEC source: 0001127602-17-008875 · form4.xml · derivative · entry 5 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,033 Underlying: Common Stock · 96,033 shares Expires 2022-02-24 F2 · derivative.exercise_date: Stock options vest as follows: 24,008 options vest one (1) year from the date of grant, 24,008 options vest two (2) years from the date of grant, 24,008 options vest (3) years from the date of grant, and 24,009 options vest four (4) years from the date of grant. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 19:31 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 19,925 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-008875 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 386,440 F1 · security: Consists of 19,925 unvested restricted stock units that vest as follows: 4,981 shares vest one (1) year from the date of issuance, 4,981 shares vest two (2) years from the date of issuance, 4,981 shares vest three (3) years from the date of issuance, and 4,982 shares vest four (4) years from the date of issuance. Read SEC document |
| February 22, 2017 Filed Feb 23, 2017 13:37 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 2,866 | $88.40 | $253,354.40 |
DisclosureSEC source: 0001127602-17-007912 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 366,515 Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $87.97 | $17,594.00 |
DisclosureSEC source: 0001127602-17-008154 · form4.xml · nonDerivative · entry 26 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 369,919 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $87.96 | $8,796.00 |
DisclosureSEC source: 0001127602-17-008154 · form4.xml · nonDerivative · entry 25 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 370,119 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 598 | $87.95 | $52,594.10 |
DisclosureSEC source: 0001127602-17-008154 · form4.xml · nonDerivative · entry 24 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 370,219 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 300 | $87.94 | $26,382.00 |
DisclosureSEC source: 0001127602-17-008154 · form4.xml · nonDerivative · entry 23 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 370,817 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $87.93 | $17,586.00 |
DisclosureSEC source: 0001127602-17-008154 · form4.xml · nonDerivative · entry 22 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 371,117 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $87.92 | $17,584.00 |
DisclosureSEC source: 0001127602-17-008154 · form4.xml · nonDerivative · entry 21 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 371,317 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $87.91 | $17,582.00 |
DisclosureSEC source: 0001127602-17-008154 · form4.xml · nonDerivative · entry 20 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 371,517 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $87.90 | $17,580.00 |
DisclosureSEC source: 0001127602-17-008154 · form4.xml · nonDerivative · entry 19 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 371,717 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $87.90 | $8,789.50 |
DisclosureSEC source: 0001127602-17-008154 · form4.xml · nonDerivative · entry 18 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 371,917 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 600 | $87.88 | $52,728.00 |
DisclosureSEC source: 0001127602-17-008154 · form4.xml · nonDerivative · entry 17 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 372,017 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,000 | $87.87 | $87,870.00 |
DisclosureSEC source: 0001127602-17-008154 · form4.xml · nonDerivative · entry 16 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 372,617 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $87.87 | $8,786.50 |
DisclosureSEC source: 0001127602-17-008154 · form4.xml · nonDerivative · entry 15 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 373,617 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 734 | $87.86 | $64,489.24 |
DisclosureSEC source: 0001127602-17-008154 · form4.xml · nonDerivative · entry 14 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 373,717 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $87.85 | $8,785.00 |
DisclosureSEC source: 0001127602-17-008154 · form4.xml · nonDerivative · entry 13 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,451 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 148 | $87.84 | $13,000.32 |
DisclosureSEC source: 0001127602-17-008154 · form4.xml · nonDerivative · entry 12 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,551 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $87.83 | $8,783.00 |
DisclosureSEC source: 0001127602-17-008154 · form4.xml · nonDerivative · entry 11 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,699 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $87.82 | $17,564.00 |
DisclosureSEC source: 0001127602-17-008154 · form4.xml · nonDerivative · entry 10 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,799 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 452 | $87.81 | $39,690.12 |
DisclosureSEC source: 0001127602-17-008154 · form4.xml · nonDerivative · entry 9 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,999 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $87.81 | $8,780.50 |
DisclosureSEC source: 0001127602-17-008154 · form4.xml · nonDerivative · entry 8 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,451 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $87.80 | $17,560.00 |
DisclosureSEC source: 0001127602-17-008154 · form4.xml · nonDerivative · entry 7 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,551 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $87.80 | $17,559.00 |
DisclosureSEC source: 0001127602-17-008154 · form4.xml · nonDerivative · entry 6 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,751 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 906 | $87.78 | $79,528.68 |
DisclosureSEC source: 0001127602-17-008154 · form4.xml · nonDerivative · entry 5 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,951 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 720 | $87.77 | $63,194.40 |
DisclosureSEC source: 0001127602-17-008154 · form4.xml · nonDerivative · entry 4 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 376,857 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.